(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.78%) $83.20
(-1.16%) $1.619
(-0.03%) $2 346.50
(-0.16%) $27.49
(0.26%) $924.50
(-0.10%) $0.934
(-0.07%) $11.02
(-0.16%) $0.799
(0.00%) $92.17
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.71%
@ $64.15
Išleistas: 26 bal. 2024 @ 20:48
Grąža: -0.14%
Ankstesnis signalas: bal. 25 - 22:50
Ankstesnis signalas:
Grąža: 2.40 %
Live Chart Being Loaded With Signals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide...
Stats | |
---|---|
Šios dienos apimtis | 946 213 |
Vidutinė apimtis | 1.09M |
Rinkos kapitalizacija | 10.07B |
EPS | $0 ( 2024-02-01 ) |
Kita pelno data | ( $0.460 ) 2024-05-01 |
Last Dividend | $0.0800 ( 2023-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 46.09 |
ATR14 | $1.869 (2.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Bohnen Shane | Sell | 2 259 | Restricted Stock Units |
2024-04-03 | Bohnen Shane | Buy | 2 259 | Common Stock |
2024-04-03 | Bohnen Shane | Sell | 747 | Common Stock |
2024-03-07 | Nusse Roeland | Sell | 10 400 | Common Stock |
2024-02-01 | Geist William | Sell | 1 111 | Common Stock |
INSIDER POWER |
---|
3.67 |
Last 99 transactions |
Buy: 1 979 464 | Sell: 2 067 622 |
Tūris Koreliacija
Bio-Techne Corp Koreliacija
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SVAC | -0.935 |
TLGT | -0.901 |
RMRM | -0.897 |
PAIC | -0.887 |
FEYE | -0.864 |
SVOK | -0.851 |
TEAM | -0.842 |
UBOH | -0.834 |
TRIN | -0.833 |
INZY | -0.827 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Bio-Techne Corp Koreliacija - Valiuta/Žaliavos
Bio-Techne Corp Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $1.14B |
Bruto pelnas: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2023 |
Pajamos: | $1.14B |
Bruto pelnas: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2022 |
Pajamos: | $1.11B |
Bruto pelnas: | $756.50M (68.42 %) |
EPS: | $1.730 |
FY | 2021 |
Pajamos: | $931.03M |
Bruto pelnas: | $632.85M (67.97 %) |
EPS: | $0.867 |
Financial Reports:
No articles found.
Bio-Techne Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0625 | 2008-10-30 |
Last Dividend | $0.0800 | 2023-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-24 | |
Next Payout Date | N/A | |
# dividends | 61 | -- |
Total Paid Out | $4.63 | -- |
Avg. Dividend % Per Year | 0.25% | -- |
Score | 4.89 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.04 | |
Div. Directional Score | 8.94 | -- |
Year | Amount | Yield |
---|---|---|
2008 | $0.0625 | 0.37% |
2009 | $0.253 | 1.57% |
2010 | $0.263 | 1.53% |
2011 | $0.273 | 1.64% |
2012 | $0.285 | 1.66% |
2013 | $0.303 | 1.75% |
2014 | $0.313 | 1.33% |
2015 | $0.320 | 1.40% |
2016 | $0.320 | 1.45% |
2017 | $0.320 | 1.25% |
2018 | $0.320 | 0.97% |
2019 | $0.320 | 0.90% |
2020 | $0.320 | 0.58% |
2021 | $0.320 | 0.41% |
2022 | $0.320 | 0.26% |
2023 | $0.320 | 0.39% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.196 | 1.500 | 6.08 | 9.13 | [0 - 0.5] |
returnOnAssetsTTM | 0.0821 | 1.200 | 7.26 | 8.72 | [0 - 0.3] |
returnOnEquityTTM | 0.115 | 1.500 | 9.84 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.225 | -1.000 | 7.75 | -7.75 | [0 - 1] |
currentRatioTTM | 4.37 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.54 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.962 | 1.500 | 5.77 | 8.65 | [0.2 - 2] |
debtRatioTTM | 0.203 | -1.500 | 6.61 | -9.91 | [0 - 0.6] |
interestCoverageTTM | 20.76 | 1.000 | 3.42 | 3.42 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.28 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.283 | -1.500 | 8.87 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.671 | 1.000 | 2.15 | 2.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.235 | 1.000 | 7.31 | 7.31 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.497 | 1.000 | 8.35 | 8.35 | [0.2 - 2] |
assetTurnoverTTM | 0.419 | 0.800 | -0.538 | -0.430 | [0.5 - 2] |
Total Score | 11.84 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 45.02 | 1.000 | 5.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.115 | 2.50 | 9.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.52 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.500 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.225 | 1.500 | 7.75 | -7.75 | [0 - 1] |
pegRatioTTM | 0.335 | 1.500 | -1.100 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.241 | 1.000 | 6.46 | 0 | [0.1 - 0.5] |
Total Score | 6.04 |
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.